UroGen Pharma (URGN) Earnings Date & Reports

Key Takeaways

• Total revenue reached $89.0 million, up sharply from $27.5 million a year earlier, though it came in slightly below consensus estimates of about $90.6 million.
• The net loss narrowed dramatically to $1.5 million, or $0.03 per share, versus $33.3 million, or $0.69 per share, in the prior-year quarter, beating consensus EPS expectations.
• Zesturi generated $68.0 million in net product revenue, a 35% sequential increase driven by broader prescriber adoption and growing repeat utilization.
• Jelmyto posted $21 million in revenue, and management updated full-year Jelmyto guidance to approximately $90 million.
• The FDA accepted UroGen's New Drug Application (NDA) for UGN-103 and assigned a PDUFA goal date of June 14, 2027.
• Cash, cash equivalents, and marketable securities totaled $90.5 million at quarter end.
• For additional context, explore UroGen's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover actionable ideas across the market with Trending AI Robots.

Earnings Context and Why It Matters

UroGen Pharma's third-quarter report is a pivotal checkpoint in the company's transition from clinical-stage developer to a scaling commercial business. The quarter tested whether Zesturi, its flagship treatment for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC), could sustain its launch momentum after a strong second quarter. With revenue more than tripling year over year and the net loss narrowing to near breakeven, the results offer investors a clearer read on the company's path to profitability. The report also carried major pipeline news, including FDA acceptance of the UGN-103 application, making this a quarter with both commercial and regulatory significance.

Reported Results

UroGen Pharma reported total revenue of $89.0 million for the third quarter ended September 30, 2026, compared with $27.5 million in the same period a year ago. The figure fell narrowly short of consensus estimates near $90.6 million. Net loss was $1.5 million, or $0.03 per share, a significant improvement from a net loss of $33.3 million, or $0.69 per share, in the third quarter of 2025 — and better than the consensus EPS estimate of a $0.05 loss.

Product-level performance drove the top line. Zesturi contributed $68.0 million in net product revenue, up 35% quarter over quarter. Jelmyto, used to treat low-grade upper tract urothelial cancer (UTUC), generated $21 million, down from $22 million in the second quarter due in part to a one-time gross-to-net adjustment. Research and development (R&D) expenses rose to $26.0 million from $14.0 million a year earlier, reflecting investment in UGN-103 and other pipeline programs.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing data-driven ideas across sectors like healthcare and biotechnology.

Market Reaction and Investor Sentiment

Despite a strong bottom-line beat and robust Zesturi growth, UroGen shares slid roughly 10% following the release, reflecting investor sensitivity to the modest revenue miss and a tempered near-term outlook. The company reiterated expectations for quarter-over-quarter Zesturi growth while acknowledging typical holiday-season seasonality in the fourth quarter. Sentiment also weighed the disclosure that clinical trials, including UroGen's own UGN-104 program, are creating competitive headwinds for Jelmyto patient starts. The market's response underscores how heavily the stock is now tied to launch execution and the pace of Zesturi's adoption among urology practices.

Forward Outlook and Key Factors to Monitor

Investors will be watching several catalysts in the quarters ahead. The most important is the continued scaling of Zesturi. Management pointed to encouraging adoption metrics — unique prescribers grew to 662 from 452 in the prior quarter, and repeat prescribers now represent about 50% of total writers. Sustaining this trajectory will be central to reaching the profitability the company is targeting with its existing capital resources.

Regulatory milestones also loom large. The FDA's acceptance of the UGN-103 NDA, with a PDUFA (Prescription Drug User Fee Act) goal date of June 14, 2027, sets up a potential approval that could extend the Zesturi franchise. UroGen plans to seek a permanent reimbursement J-code, with a full commercial launch targeted for 2028.

Beyond UGN-103, the company expects to complete enrollment in the UGN-104 Phase 3 trial by late 2026 or early 2027, while UGN-501, an investigational oncolytic virus, has begun dosing with initial clinical data anticipated in 2027. On the cost side, rising R&D and selling, general, and administrative (SG&A) spending will bear watching if revenue growth decelerates. For now, the balance of Zesturi's commercial momentum against pipeline investment remains the defining theme for UroGen's next several quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations